"We hope Gamaleya [research institute] will join Covax on the condition it receives WHO emergency use listing," the WHO said.
The WHO held a session to discuss additional data related to the Russian vaccine on Monday. The next round of negotiations is slated for 15 February.
Sputnik V, developed by the Gamaleya Epidemiology and Microbiology Center and registered by the Russian Ministry of Health on 11 August, was the world's first vaccine against the novel coronavirus. The vaccine consists of two components that are applied to a person within an interval of 21 days. The phase 3 trial included over 20,000 adult volunteers, and is still ongoing, as it aims at including 40,000 participants.
The Russian Direct Investment Fund, which promotes Sputnik V in international market, expects that the EU’s regulator may approve the vaccine in early March.